Presentations highlight investigational trenibotulinumtoxinE in the treatment of glabellar lines and other new findings across the company’s portfolio.
Allergan Aesthetics, an AbbVie company, will highlight pivotal data for its investigational botulinum neurotoxin serotype E (trenibotulinumtoxinE) during the 2025 American Society for Dermatologic Surgery Annual Meeting, Nov. 13–16 in Chicago.
Phase 3 clinical study results for trenibotulinumtoxinE in the treatment of glabellar lines in toxin-naïve participants will be featured in the meeting’s Cosmetic Oral Abstract Presentations: Top Ten Session, alongside other research across the company’s neuromodulator and filler portfolio, including results from a Phase 4 study evaluating natural outcomes and patient satisfaction in a diverse population following use of 64 units of Botox Cosmetic for treatment of upper facial lines.
“Allergan Aesthetics leads the industry by consistently delivering clinically differentiated products to patients and providers through new indications and expanded uses for existing treatments, as well as novel investigational assets that meet the evolving needs of the market,” says John Maltman, vice president, global aesthetics medical affairs of Allergan Aesthetics, in a release. “The scientific and clinical data reported at this year’s congress demonstrate how we continue to drive evidence-based innovation across our robust product portfolio, with the goal of improving the standard of care and personalized outcomes for all.”
Abstract Presentations and Panel Discussion
Three abstracts were accepted for live presentation in the Cosmetic Oral Abstract Presentations: Top Ten Session, where primary authors will present in-person on Nov 13:
- Safety and Efficacy of TrenibotulinumtoxinE for Treating Glabellar Lines in Toxin-Naïve Participants: Results from a Multicenter Phase 3 Study (presented by Rosalyn George, MD).
- Patient-Reported Satisfaction, Natural Look, and Improvement in Appearance-Related Psychological Impact from Fast-Acting TrenibotulinumtoxinE Treatment for Glabellar Lines: Phase 3 Study Results (presented by Robert Weiss, MD).
- High Patient Satisfaction with Natural-Looking Results after OnabotulinumtoxinA Treatment for Upper Facial Lines in a Diverse Population: A Phase IV, Open Label Multicenter Study (presented by Vince Bertucci, MD).
Additionally, the company will host an expert panel discussion exploring a recently published “Hyaluronic Acid Injectable Fillers Report” and provide education on the current use, facts, and real-world satisfaction data for hyaluronic acid injectable fillers.
Panel participants include Dr Sabrina Fabi, Dr Terrence Keaney, Dr Kavita Mariwalla, and Dr Patricia Olgilvie and will be moderated by Melanie Rud.
Other presentations from Allergan Aesthetics highlight new data on sequential administration of trenibotulinumtoxinE and Botox Cosmetic for glabellar lines; the benefit of long-term, repeated use of Botox Cosmetic for upper facial lines; the safety and effectiveness of Skinvive by Juvederm for the improvement of neck appearance; as well as survey results outlining facial and body aesthetic concerns and treatment trends following medical weight loss.
ID 204366604 © Viacheslav Iacobchuk | Dreamstime.com
